You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalation

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalation

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023276020
Dec 202342015
Jan 20247705
Feb 202444012
Mar 20244805
Apr 20243805
May 20244205
Jun 20242806
Jul 20242204
Aug 20242002
Sep 202440013
Oct 20244207
Nov 20242606
Dec 20247009
Jan 202539026
Feb 2025604
Mar 2025008
Apr 2025003
May 2025007
Jun 2025105
Total8610167